BiotechTube
Home/Prilenia Therapeutics/Michael Hayden
MH

Michael Hayden

Chief Executive Officer

Prilenia Therapeutics

Therapeutic Areas

Huntington's diseaseAmyotrophic lateral sclerosisNeurodegenerative diseasesNeurodevelopmental disorders

Prilenia Therapeutics Pipeline

DrugIndicationPhase
PridopidineHuntington's diseasePhase 3